United States

PepGen Inc (PEPG)

Track

PepGen Inc. experienced one insider trading transaction over the past ninety days, involving a planned sale by the Chief Technical Officer. This activity follows recent positive stock performance. Previous filings indicate executives frequently utilized scheduled divestment programs, while institutional entities previously engaged in significant equity acquisitions prior to the latest reported results financiers.
Ticker: PEPG Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for PepGen Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Kasraian Kasra Chief Technical Officer Officer
Transaction date
Planned sale
Price
293.00
Quantity 19,762 +47.0%
Value US$3,219,582
STRECK PAUL EVP, Head of R&D Officer
Transaction date
Planned sale
Price
175.26
Quantity 91,646 -30.9%
Value US$1,149,591
STRECK PAUL EVP, Head of R&D Officer
Transaction date
Planned sale
Price
406.25
Quantity 17,079 -40.9%
Value US$1,364,906
Donnelly Noel Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.33
Quantity 52 -0.0%
Value US$329
Donnelly Noel Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.23
Quantity 2,032 -1.8%
Value US$12,659
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
6.33
Quantity 131 -0.0%
Value US$829
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
6.23
Quantity 5,144 -1.7%
Value US$32,047
Oxford Science Enterprises plc Former 10% Owner
Transaction date
Purchase
Price
3.20
Quantity 200,000 +4.2%
Value US$640,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
3.20
Quantity 9,375,000 +102.1%
Value US$30,000,000
STRECK PAUL EVP, Head of R&D Officer
Transaction date
Planned purchase
Price
1.24
Quantity 8,375 +43.1%
Value US$10,393
2.7
McArthur James G President and CEO Executive Director
Transaction date
Purchase
Price
1.36
Quantity 10,000 +9.6%
Value US$13,550
2.7
McArthur James G President and CEO Executive Director
Transaction date
Purchase
Price
1.15
Quantity 41,500 +66.5%
Value US$47,725
DeLena Mary Beth General Counsel Officer
Transaction date
Planned sale
Price
1.68
Quantity 1,432 -47.7%
Value US$2,406
Donnelly Noel Chief Financial Officer Officer
Transaction date
Planned sale
Price
1.68
Quantity 1,527 -47.7%
Value US$2,565
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.06
Quantity 7,571 -100.0%
Value US$136,741
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.01
Quantity 201 -100.0%
Value US$3,619
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.20
Quantity 12,625 -100.0%
Value US$229,804
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.00
Quantity 5,901 -100.0%
Value US$106,247
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.04
Quantity 3,288 -100.0%
Value US$59,331
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.07
Quantity 37 -100.0%
Value US$669
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.01
Quantity 875 -100.0%
Value US$15,760
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.19
Quantity 9,260 -100.0%
Value US$168,427
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.06
Quantity 1,086 -100.0%
Value US$19,615
Mellion Michelle L Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.04
Quantity 500 -100.0%
Value US$9,022
Mellion Michelle L SVP, Clinical Development Officer
Transaction date
Planned sale
Price
18.00
Quantity 1,411 -100.0%
Value US$25,398
Mellion Michelle L SVP, Clinical Development Officer
Transaction date
Planned sale
Price
18.09
Quantity 7,245 -100.0%
Value US$131,062
MICHELLE L. MELLION Officer Officer
Transaction date
Proposed sale
Price
15.76
Quantity 50,000
Value US$788,000
3.3
NIELS SVENSTRUP Officer Officer
Transaction date
Proposed sale
Price
13.65
Quantity 10,000
Value US$136,500
3.3
Svenstrup Niels SVP, Chem. Mfg & Controls Officer
Transaction date
Planned sale
Price
13.41
Quantity 10,000 -100.0%
Value US$134,100
Goyal Jaya Officer Officer
Transaction date
Proposed sale
Price
17.75
Quantity 116,187
Value US$2,062,376
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
10.64
Quantity 2,557,593 +38.6%
Value US$27,212,790
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned purchase
Price
4.17
Quantity 1,694 +inf%
Value US$7,056
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
16.04
Quantity 2,381 -100.0%
Value US$38,188
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
16.23
Quantity 8,419 -100.0%
Value US$136,618
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
16.18
Quantity 18,150 -100.0%
Value US$293,660
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
16.06
Quantity 500 -100.0%
Value US$8,028
2.7
McArthur James G President and CEO Executive Director
Transaction date
Planned sale
Price
16.04
Quantity 1,800 -100.0%
Value US$28,863
2.7
JAMES MCARTHUR Officer Officer
Transaction date
Proposed sale
Price
14.75
Quantity 31,250
Value US$460,938
Goyal Jaya EVP, Res. & Preclin. Dev. Officer
Transaction date
Planned sale
Price
20.00
Quantity 392 -100.0%
Value US$7,840
Goyal Jaya EVP, Res. & Preclin. Dev. Officer
Transaction date
Planned sale
Price
17.00
Quantity 644 -100.0%
Value US$10,948
Goyal Jaya EVP, Res. & Preclin. Dev. Officer
Transaction date
Planned sale
Price
17.18
Quantity 3,679 -100.0%
Value US$63,213
Goyal Jaya EVP, Res. & Preclin. Dev. Officer
Transaction date
Planned sale
Price
17.04
Quantity 1,677 -100.0%
Value US$28,568
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 249,749 +23.7%
Value US$2,996,988
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 2,979,451 +81.8%
Value US$35,753,412
2.8
Flynn James E Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 208,333 +77.6%
Value US$2,499,996
2.8
Flynn James E Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 208,333 +77.6%
Value US$2,499,996
2.2
KEATING LAURIE Non-Executive Director
Transaction date
Purchase
Price
12.00
Quantity 4,166 +inf%
Value US$49,992
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-26 2026-05-21 PlS Planned sale
Kasraian Kasra

Chief Technical Officer

Officer
19,762 +47.0%
293.00
US$3,219,582 		19,762 +47.0% 293.00 US$3,219,582
2026-03-06 2026-03-04 PlS Planned sale
STRECK PAUL

EVP, Head of R&D

Officer
91,646 -30.9%
175.26
US$1,149,591 		91,646 -30.9% 175.26 US$1,149,591
2026-03-06 2026-03-04 PlS Planned sale
STRECK PAUL

EVP, Head of R&D

Officer
17,079 -40.9%
406.25
US$1,364,906 		17,079 -40.9% 406.25 US$1,364,906
2026-03-06 2026-03-04 PlS Planned sale
Donnelly Noel

Chief Financial Officer

Officer
52 -0.0%
6.33
US$329 		52 -0.0% 6.33 US$329
2026-03-06 2026-03-04 PlS Planned sale
Donnelly Noel

Chief Financial Officer

Officer
2,032 -1.8%
6.23
US$12,659 		2,032 -1.8% 6.23 US$12,659
2026-03-06 2026-03-04 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
131 -0.0%
6.33
US$829 		131 -0.0% 6.33 US$829
2026-03-06 2026-03-04 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
5,144 -1.7%
6.23
US$32,047 		5,144 -1.7% 6.23 US$32,047
2025-10-01 2025-09-30 B Purchase
Oxford Science Enterprises plc

Former 10% Owner
200,000 +4.2%
3.20
US$640,000 		200,000 +4.2% 3.20 US$640,000
2025-09-30 2025-09-26 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
9,375,000 +102.1%
3.20
US$30,000,000 		9,375,000 +102.1% 3.20 US$30,000,000
2025-06-02 2025-05-30 PP Planned purchase
STRECK PAUL

EVP, Head of R&D

Officer
8,375 +43.1%
1.24
US$10,393 		8,375 +43.1% 1.24 US$10,393
2025-04-22 2025-04-17 B Purchase
2.7
McArthur James G

President and CEO

Executive Director
10,000 +9.6%
1.36
US$13,550 		10,000 +9.6% 1.36 US$13,550
2025-04-09 2025-04-08 B Purchase
2.7
McArthur James G

President and CEO

Executive Director
41,500 +66.5%
1.15
US$47,725 		41,500 +66.5% 1.15 US$47,725
2025-02-26 2025-02-26 PlS Planned sale
DeLena Mary Beth

General Counsel

Officer
1,432 -47.7%
1.68
US$2,406 		1,432 -47.7% 1.68 US$2,406
2025-02-26 2025-02-26 PlS Planned sale
Donnelly Noel

Chief Financial Officer

Officer
1,527 -47.7%
1.68
US$2,565 		1,527 -47.7% 1.68 US$2,565
2024-07-26 2024-07-25 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
7,571 -100.0%
18.06
US$136,741 		7,571 -100.0% 18.06 US$136,741
2024-07-26 2024-07-24 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
201 -100.0%
18.01
US$3,619 		201 -100.0% 18.01 US$3,619
2024-07-19 2024-07-18 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
12,625 -100.0%
18.20
US$229,804 		12,625 -100.0% 18.20 US$229,804
2024-07-16 2024-07-16 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
5,901 -100.0%
18.00
US$106,247 		5,901 -100.0% 18.00 US$106,247
2024-07-16 2024-07-12 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
3,288 -100.0%
18.04
US$59,331 		3,288 -100.0% 18.04 US$59,331
2024-07-03 2024-07-02 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
37 -100.0%
18.07
US$669 		37 -100.0% 18.07 US$669
2024-07-03 2024-07-01 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
875 -100.0%
18.01
US$15,760 		875 -100.0% 18.01 US$15,760
2024-06-26 2024-06-24 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
9,260 -100.0%
18.19
US$168,427 		9,260 -100.0% 18.19 US$168,427
2024-06-13 2024-06-12 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
1,086 -100.0%
18.06
US$19,615 		1,086 -100.0% 18.06 US$19,615
2024-06-13 2024-06-11 PlS Planned sale
Mellion Michelle L

Chief Medical Officer

Officer
500 -100.0%
18.04
US$9,022 		500 -100.0% 18.04 US$9,022
2024-06-07 2024-06-06 PlS Planned sale
Mellion Michelle L

SVP, Clinical Development

Officer
1,411 -100.0%
18.00
US$25,398 		1,411 -100.0% 18.00 US$25,398
2024-06-07 2024-06-05 PlS Planned sale
Mellion Michelle L

SVP, Clinical Development

Officer
7,245 -100.0%
18.09
US$131,062 		7,245 -100.0% 18.09 US$131,062
2024-06-05 2024-06-05 PrS Proposed sale
MICHELLE L. MELLION

Officer

Officer
50,000
15.76
US$788,000 		50,000 15.76 US$788,000
2024-05-17 2024-05-17 PrS Proposed sale
3.3
NIELS SVENSTRUP

Officer

Officer
10,000
13.65
US$136,500 		10,000 13.65 US$136,500
2024-05-17 2024-05-17 PlS Planned sale
3.3
Svenstrup Niels

SVP, Chem. Mfg & Controls

Officer
10,000 -100.0%
13.41
US$134,100 		10,000 -100.0% 13.41 US$134,100
2024-03-12 2024-03-12 PrS Proposed sale
Goyal Jaya

Officer

Officer
116,187
17.75
US$2,062,376 		116,187 17.75 US$2,062,376
2024-02-13 2024-02-09 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
2,557,593 +38.6%
10.64
US$27,212,790 		2,557,593 +38.6% 10.64 US$27,212,790
2023-12-05 2023-11-30 PP Planned purchase
2.7
McArthur James G

President and CEO

Executive Director
1,694 +inf%
4.17
US$7,056 		1,694 +inf% 4.17 US$7,056
2023-06-09 2023-06-08 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
2,381 -100.0%
16.04
US$38,188 		2,381 -100.0% 16.04 US$38,188
2023-06-08 2023-06-07 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
8,419 -100.0%
16.23
US$136,618 		8,419 -100.0% 16.23 US$136,618
2023-06-08 2023-06-06 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
18,150 -100.0%
16.18
US$293,660 		18,150 -100.0% 16.18 US$293,660
2023-06-06 2023-06-05 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
500 -100.0%
16.06
US$8,028 		500 -100.0% 16.06 US$8,028
2023-06-06 2023-06-02 PlS Planned sale
2.7
McArthur James G

President and CEO

Executive Director
1,800 -100.0%
16.04
US$28,863 		1,800 -100.0% 16.04 US$28,863
2023-06-02 2023-06-02 PrS Proposed sale
2.7
JAMES MCARTHUR

Officer

Officer
31,250
14.75
US$460,938 		31,250 14.75 US$460,938
2023-03-28 2023-03-24 PlS Planned sale
Goyal Jaya

EVP, Res. & Preclin. Dev.

Officer
392 -100.0%
20.00
US$7,840 		392 -100.0% 20.00 US$7,840
2023-02-08 2023-02-08 PlS Planned sale
Goyal Jaya

EVP, Res. & Preclin. Dev.

Officer
644 -100.0%
17.00
US$10,948 		644 -100.0% 17.00 US$10,948
2023-02-08 2023-02-07 PlS Planned sale
Goyal Jaya

EVP, Res. & Preclin. Dev.

Officer
3,679 -100.0%
17.18
US$63,213 		3,679 -100.0% 17.18 US$63,213
2023-02-08 2023-02-06 PlS Planned sale
Goyal Jaya

EVP, Res. & Preclin. Dev.

Officer
1,677 -100.0%
17.04
US$28,568 		1,677 -100.0% 17.04 US$28,568
2022-05-12 2022-05-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
249,749 +23.7%
12.00
US$2,996,988 		249,749 +23.7% 12.00 US$2,996,988
2022-05-12 2022-05-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
2,979,451 +81.8%
12.00
US$35,753,412 		2,979,451 +81.8% 12.00 US$35,753,412
2022-05-10 2022-05-10 B Purchase
2.8
Flynn James E
Large shareholder
208,333 +77.6%
12.00
US$2,499,996 		208,333 +77.6% 12.00 US$2,499,996
2022-05-10 2022-05-10 B Purchase
2.8
Flynn James E
Large shareholder
208,333 +77.6%
12.00
US$2,499,996 		208,333 +77.6% 12.00 US$2,499,996
2023-01-19 2022-05-06 B Purchase
2.2
KEATING LAURIE
Non-Executive Director
4,166 +inf%
12.00
US$49,992 		4,166 +inf% 12.00 US$49,992
Explore more

More insider trading research around PepGen Inc

More insider trades in United States
Insider trading in North America